The Great Rebalancing: Why US Pharma Is Now Buying Its Pipeline From China

The Great Rebalancing: Why US Pharma Is Now Buying Its Pipeline From China

For most of the last two decades, the flow of biopharmaceutical innovation ran one direction: Western-discovered molecules, licensed or sold into China for local development and commercialization. That flow has reversed. Large-cap US and European drugmakers are now the buyers, and Chinese biotechs are increasingly the sellers of choice — not out of charity or geopolitical goodwill, but because the assets, the pricing, and the pipeline economics have become too compelling to ignore.

The numbers:

• $137.7B — Greater China out-licensing value in 2025, up roughly 10x from 2021's $13.9B
• $60B — Q1 2026 alone, up 73% year-over-year, per China's National Medical Products Administration
• ~1/3 → 2/3 — Share of global licensing spend tied to China-origin assets, 2025 actual to 2026 projected

What Changed

Three forces are converging to pull US pharma toward China-originated assets at a pace that would have seemed implausible five years ago.

The patent cliff is real and it is close. Industry advisory estimates point to as much as $200 billion in annual global pharmaceutical revenue at risk from patent expirations between 2026 and 2030, with Merck's Januvia/Janumet franchise and the Pfizer/Astellas oncology drug Xtandi among the near-term exposures. Licensing a China-developed, already-de-risked clinical asset is materially cheaper and faster than either full M&A or ground-up internal R&D.

China's pipeline has genuinely matured. This is not simply a cost play. Analysts at Pitchbook note that China's biotech ecosystem has "gained the lead" in generating early-stage drug candidates, and that edge is expected to persist for several years as innovation remains comparatively underfunded elsewhere. The clearest proof point: a homegrown PD-1/VEGF bispecific antibody, ivonescimab, beat Merck's Keytruda head-to-head in a Phase 3 lung cancer trial in China — a result that triggered a wave of competing bispecific licensing deals, including Pfizer's.

Deal structures favor the buyer. According to JPMorgan's Q1 2026 Biopharma Licensing and Venture Report, upfront cash represented just 6% of total announced deal value in the quarter, with the balance pushed into milestone- and royalty-based payments. Large pharma is effectively "acquiring de-risked innovation hubs at a fraction of the cost of full M&A," in Pitchbook's framing, while keeping the bulk of the capital at risk contingent on the drug actually working and reaching the market.

The Impact: A Widening Gap at Home

The most consequential effect of this shift isn't in Shanghai or Shenyang — it's showing up in the US early-stage funding market. Venture capital has not walked away from biotech, but it has become highly selective about where it plays, and the selectivity is compounding the China dynamic rather than offsetting it.

• Seed and Series A funding is at a post-pandemic low. JPMorgan tracked just 50 seed and Series A deals worth $2.3 billion in Q1 2026, down from 60 deals worth $3.7 billion in the same period of 2025. Later-stage rounds, by contrast, are up: 51 Series B-and-later deals raised $4.5 billion in the same quarter.
• Capital is chasing de-risked assets, and those assets increasingly originate in China. About two-thirds of US venture rounds in the first half of 2026 went to companies that already had a drug candidate in human testing — many of them built around licensed-in Chinese compounds rather than homegrown discovery programs.
• The "next wave" question has no clear answer yet. Industry voices, including EY-Parthenon's Ashwin Singhania, have flagged a "grave concern" about where the next generation of early-stage US innovation comes from, particularly against a backdrop of NIH funding cuts to basic research — a gap whose consequences may not surface for a decade.

Net effect: US pharma's balance sheets and pipelines are healthier in the near term because China-sourced licensing has become a capital-efficient substitute for internal R&D and full M&A. But the domestic seed-to-Series A ecosystem — the layer that historically produced the assets now being licensed in from abroad — is thinner than it was three years ago.

The Skeptic's Case

Deal-flow dependency. Licensing is currently "carrying the ecosystem," in one industry framing. If Chinese deal flow slows — whether for regulatory, competitive, or geopolitical reasons — the multiple compression risk for companies and investors positioned around continued deal volume is real.

Milestone-heavy economics overstate near-term cash. With upfront payments running near 6% of headline deal value, the eye-catching multibillion-dollar totals reported in the press materially overstate what changes hands today. Realized value depends on years of clinical and regulatory execution.

Policy risk is rising on both sides. The BIOSECURE Act, signed into law in December 2025 as part of the FY2026 NDAA, currently targets CDMO and manufacturing relationships with a five-year safe harbor, but scope-creep toward licensing and IP arrangements remains a live possibility. Separately, a bipartisan congressional effort would add biotech to the Treasury Department's outbound investment screening list, which could complicate future deal structures. On the domestic side, proposed most-favored-nation drug pricing policy has prompted 87% of VCs surveyed by Incubate to say federal price controls would limit US biotech investment further — a dynamic that could, paradoxically, push more capital toward externally sourced, de-risked assets rather than away from them.

Balance of views: Proponents of continued deal flow point to genuine scientific merit, faster patient access to novel mechanisms, and capital efficiency for cash-constrained developers. Critics warn of a widening domestic innovation gap, concentration risk in a single geography's regulatory and political environment, and the risk that today's favorable deal terms compress as more Western capital competes for the same asset pool. Both dynamics appear to be playing out simultaneously.

What We're Watching

• Whether US Series A funding stabilizes in the second half of 2026 or continues to lag Series B-and-later activity.
• Any legislative movement on outbound investment screening for biotech, and whether BIOSECURE's scope is expanded beyond manufacturing.
• Deal-term evolution — specifically whether upfront percentages rise as competition for top China-origin assets intensifies, which would signal a shift in bargaining power back toward licensors.
• Obesity/metabolic and cell and gene therapy licensing, flagged by multiple trackers as the next high-value categories after oncology.

Sources: National Medical Products Administration; PharmCube; JPMorgan Q1 2026 Biopharma Licensing and Venture Report; Pitchbook (Jan. 2026, Ben Zercher); EY 2026 Biotech Beyond Borders Report; BioPharma Dive; Reuters; Bloomberg; South China Morning Post; Pfizer press releases; STAT News; PharmaVoice; Incubate 2026 investor survey.